RxDoctor Payments Data

Amir Lubarsky, MD

Internal Medicine · Jupiter, FLNPI 1245219047

Payments from drug & device makers

$1,439in general payments, 2019–2025

Across 105 payments — averaging $13.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$394
  • Novartis$163
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$129
  • Amgen$114
  • Pfizer$106
  • AstraZeneca$92
  • plus $442 from 10 others

What the payments were for

  • Food & beverage$1,439100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,439 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$115,063
Medicare patients
289
Services billed
2,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide400$477,258
Repatha SureclickEvolocumab150$182,436
OzempicSemaglutide88$108,784
EliquisApixaban53$65,708
Repatha SyringeEvolocumab45$61,405
Praluent PenAlirocumab54$58,947
XareltoRivaroxaban37$38,708
RybelsusSemaglutide18$23,460
MyrbetriqMirabegron26$15,916
PaxlovidNirmatrelvir/Ritonavir45$5,718
Rosuvastatin Calcium246$4,798
VesicareSolifenacin Succinate12$4,658
Nebivolol Hcl43$3,803
Escitalopram Oxalate158$3,311
Celecoxib51$3,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$55$477,258400 claims
Novo NordiskOzempic, Rybelsus$394$132,245106 claims
PfizerEliquis, Paxlovid, Premarin$106$73,491109 claims
Astellas Pharma US IncMyrbetriq, Vesicare$36$20,57438 claims
AbbVieSynthroid$61$2,89426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →